Post
VALUE-Dx initiative to tackle antimicrobial resistance in respiratory infections
World Antimicrobial Awareness Week (WAAW) is a global campaign held annually in November to improve awareness and understanding of antimicrobial …
Baudax Bio reports promising additional data for neuromuscular blockade agent
Baudax Bio revealed additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients undergoing …
Systemic sclerosis: understanding gender differences of a complex disease
Systemic sclerosis (SSc), also known as scleroderma, is a complex autoimmune disease that affects the skin and various organs in …
FibroGen’s study of DMD therapy fails to meet primary endpoint
FibroGen’s Phase III LELANTOS-1 clinical study of pamrevlumab has failed to meet the primary endpoint of Performance of the Upper …
CIRM awards grant to support Eureka’s T-cell therapy trial
The California Institute for Regenerative Medicine (CIRM) has awarded a $10.6m grant to support Eureka Therapeutics’ ARYA-2 Phase I clinical …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Cellf Bio’s first-in-human implantation of BioSphincter
Cellf Bio has reported the first human implantation of its autologous bioengineered sphincter BioSphincter in a Phase I clinical trial …
Arbutus previews Hepatitis B RNAi treatment data
Arbutus is gearing up to present preliminary safety and antiviral activity of AB-729 combination treatment in virally suppressed, HBeAg-negative subjects …
Oncternal doses first patient in trial of B cell lymphoma therapy
Oncternal Therapeutics has dosed the first patient in its Phase I/II trial of ONCT-808, a ROR1 targeting autologous CAR T …
LianBio reports positive topline data from gastric cancer therapy trial
LianBio has reported positive topline results from a Phase IIa trial of infigratinib for the treatment of locally advanced or …
QurAlis receives authorisation to initiate ALS therapy trial in EU
QurAlis has received clinical trial authorisation (CTA) in the European Union (EU) to initiate a first-in-human, Phase I ANQUR clinical …
BPGbio doses first patients in Phase II GBM therapy trial
BPGbio has dosed the first patients in a Phase II clinical trial of BPM 31510 to treat Glioblastoma Multiforme (GBM), …
ASCO 2023: blockbuster Enhertu demonstrates efficacy across multiple tumour types
At the American Society of Clinical Oncology (ASCO) Annual Meeting, 2-6 June 2023, interim results were presented for the Phase …
FDA open for feedback on GCP draft guidance
The US Food and Drug Administration (FDA) released a draft guidance with updated recommendations for good clinical practices (GCPs). The draft …
IDE clinical trial for artificial cervical disc completes enrollment
Synergy Spine Solutions has enrolled the last patient in its investigational device exemption (IDE) clinical trial. The 1-Level Synergy Disc …
ASCO 2023: Precigen reports positive early data for CAR-T therapy
New early data suggests Precigen Therapeutics’s CAR-T therapy PRGN-3005 could decrease tumour burden in advanced ovarian cancer. In Phase I data …